It has been noticed that the Darnytsia pharmaceutical company is developing new medicaments at a rapid pace and by its own bankroll expense. According to the agency’s correspondent, this was stated in an interview with Ukrinform by the Chairman of the Board of Directors of the company, Dmytro Shymkiv.

He stressed that the company has released over 40 new brands over the past five years, and 35.3 million euros have been invested in the development itself. He gave clarifying information that the line of nasal sprays, sedatives, and agents designed to regulate the physiological rhythm of the intestine has been expanded. The prescription drug category includes a balanced crystalloid solution to correct electrolyte imbalances, a gout cure, and a dual combination of antihypertensive drugs. And this is all optimal to control blood pressure.

It is also said that in 2019 the company underwent a rebranding and presented a new strategy. Thus, the company set plans for a leading position in terms of complex generics. Concentrating on the development of the product portfolio, the company follows this strategy, namely, focusing on treating the most common diseases among the population of Ukraine.

Pharmaceuticals are at the forefront of innovations all around the planet. It is pharmaceuticals that occupy one of the leading positions here. As for the Darnytsia pharmaceutical company itself, the innovation process, in this case, is ongoing and goes on non-stop, covering everyone: from employees to consumers. The company also carries out development and production work because it is a pharmaceutical company that is the largest Ukrainian manufacturer in terms of the volume of manufactured products.

Dmytro Shymkiv added that the development of new drugs here is carried out jointly with the medical community. The portfolio currently consists of 60 products at different stages of development in terms of pharmaceuticals, the registration of which is planned until 2023. This is the result of the company’s own development and cooperative action with foreign companies. The head delivered information that the company invests more than 40 percent of the total investment package every year on research work and the development of new products. The Chairman of the Board of Directors of Darnytsia Group said that pharmaceutical companies in Ukraine are not lagging behind the world in terms of technology and quality.